Exelixis, Inc. (Nasdaq:EXEL) is a biopharmaceutical company committed to the discovery, development and commercialization of new medicines with the potential to improve care and outcomes for people with cancer. Since its founding in 1994, three medicines discovered at Exelixis have progressed through clinical development to receive regulatory approval. Exelixis is focused on advancing cabozantinib, which has shown clinical anti‐tumor activity in more than 20 forms of cancer and is the subject of a broad clinical development program. For more information, please visit www.exelixis.com.